Overview

Immune Effects of Oral Insulin in Relatives at Risk for Type 1 Diabetes Mellitus (TN20)

Status:
Completed
Trial end date:
2018-03-01
Target enrollment:
Participant gender:
Summary
The study is a 2 arm, multi-center, randomized, open-labeled clinical trial designed to assess the effects of varying doses and schedules of oral insulin on immunological and metabolic markers in relatives at risk for type 1 diabetes (T1D).
Phase:
Phase 2
Details
Lead Sponsor:
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Collaborator:
Type 1 Diabetes TrialNet
Treatments:
Insulin
Insulin, Globin Zinc
Insulin, Isophane
Methamphetamine